Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance

Table 3 Operative method, outcome, tumor size, histological type, pathological stage, and adjuvant chemotherapy

	FNA+	FNA-
Number of patients	54	28
Operative method (%)
PD	59.3 (32/54)	75 (21/28)	NS1
DP	38.9 (21/54)	17.9 (5/28)
TP	1.9 (1/54)	3.6 (1/28)
Partial resection	1.9 (1/54)	3.6 (1/28)
Outcome (%)
R0	96.3 (52/54)	96.4 (27/28)	NS1
R1	3.7 (2/54)	3.6 (1/28)
R2	0 (0/54)	0 (0/28)
Tumor size (mm)	30.0 ± 1.9 SD	29.5 ± 2.5 SD	NS1
Histological type
Adenocarcinoma	53	26	NS1
Adenosquamous carcinoma	1	0
IPMC	0	2
UICC (%)
0	0 (0/54)	3.6 (1/28)	NS1
IA	3.7 (2/54)	7.1 (2/28)
IB	1.9 (1/54)	0 (0/28)
IIA	48.1 (26/54)	21.4 (6/28)
IIB	38.9 (21/54)	53.6 (15/28)
III	3.7 (2/54)	3.6 (1/28)
IV	3.7 (2/54)	10.7 (3/28)
AC administration (%)	74.1 (40/54)	50 (14/28)	P < 0.051

¹Pearson’s χ² test. FNA+: The patient group who underwent endoscopic ultrasound-guided fine-needle aspiration before surgery; FNA-: The patient group who did not undergo endoscopic ultrasound-guided fine-needle aspiration before surgery; PD: Pancreatoduodenectomy; DP: Distal pancreatectomy; TP: Total pancreatectomy; SD: Standard deviation; IPMC: Intraductal papillary mucinous carcinoma of the pancreas; UICC: Pathological stage of the Union Internationale Contre le Cancer; AC: Adjuvant chemotherapy.